2021

Professional development Vacancies
2021
Regarding amendments to the instructions for medical use of medicinal products containing indapamide (indapamide)

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing glatiramer (glatiramer)

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing hydroxycarbamide (hydroxycarbamide)

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing hydroxyzine (hydroxyzine)

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Read more
Signal based on the analysis of information from the WHO Global Database VigiBase, published by Uppsala Monitoring Centre: “Colecalciferol [vitamin D3] and eczema”

The VigiBase database received 35 individual safety reports from 10 countries of the world with the adverse reaction “Eczema” associated with the use of…

Read more
Signal from the analysis of information from the WHO Global Database VigiBase, published by the Uppsala Monitoring Centre: “COVID-19 vaccines and subacute thyroiditis”

Subacute thyroiditis (ST) is an inflammatory condition of the thyroid gland that can potentially cause symptoms similar to hyperthyroidism: tachycardia, agitation, tremor, and…

Read more
Updated safety information on COVID-19 vaccines

On 11 August 2021, the Pharmacovigilance Risk Assessment Committee (PRAC) published an update of safety information on COVID-19 vaccines. In this…

Read more
On amending the instructions for medical use of medicinal products containing octreotide (octreotide)

Following the results of the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), recommendations were issued on updating the instructions for medical use. With…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing donepezil (Donepezil)

Following the results of the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), recommendations were issued on updating the instructions for medical use, and…

Read more
Regarding amendments to the instructions for medical use of medicinal products – immune checkpoint inhibitors containing atezolizumab (Atezolizumab), durvalumab (Durvalumab), and pembrolizumab (Pembrolizumab)

Following the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), recommendations were issued regarding the update of the instructions for medical use. Taking…

Read more